Today: 9 April 2026
Applied Materials stock rebounds after Citi’s $400 target and a Taiwan order — earnings next
6 February 2026
1 min read

Applied Materials stock rebounds after Citi’s $400 target and a Taiwan order — earnings next

New York, Feb 5, 2026, 19:29 EST — After-hours

  • Applied Materials shares ended Thursday roughly 2.1% higher, closing at $303.99.
  • Citi raised its price target to $400, citing stronger signs of chipmaker spending.
  • Traders are gearing up for next week’s earnings reports alongside a delayed batch of U.S. macro data.

Applied Materials (AMAT.O) shares ended Thursday up roughly 2.1%, closing at $303.99, clawing back some losses from earlier in the week as chip stocks searched for stability. MarketWatch

The move is significant now as investors juggle two conflicting narratives: surging investment fueled by artificial intelligence and weak spots in consumer electronics. Applied’s quarterly report next week will offer one of the clearer insights into wafer fabrication equipment — the pricey machinery essential for chip manufacturing.

Citi analyst Atif Malik bumped his price target for Applied Materials to $400 from $250, maintaining a “buy” rating. He cited upbeat spending revisions among leading foundry and memory chipmakers. TipRanks

Taiwan added a fresh boost as TradingView reported Winbond Electronics spent T$7.45 billion (roughly $235 million) on machinery and equipment from Applied Materials South Eastasia. TradingView

The stock showed unusual jitters for a chip name. Shares dropped 6.6% on Wednesday, then clawed back some ground on Thursday. MarketWatch

Broader markets offered no relief. U.S. stocks fell sharply Thursday, dragged down by heavy selling in major tech names amid renewed worries over the costs tied to AI-driven capital expenditures. “This is a difficult environment for risk assets,” said Tom Hainlin, national investment strategist at U.S. Bank Wealth Management, in comments to Reuters. Reuters

Signs on semiconductor demand are diverging. Qualcomm and Arm flagged memory chip shortages that are crimping smartphone output. Qualcomm CEO Cristiano Amon called it “an industry issue on memory allocations.” Reuters

Other chip toolmakers showed mixed results but held fairly steady, as Lam Research closed up. MarketWatch

Applied, headquartered in Santa Clara, California, supplies equipment for crucial stages in chip production and operates a sizable service arm supporting customers’ fabs. Investors closely track its orders and guidance as a barometer for chipmakers’ capital expenditures, or “capex,” the funds poured into new factories and machinery.

That said, the outlook is a double-edged sword. Any sign of slowing customer spending, extended delivery schedules, or weaker demand beyond AI could sour sentiment fast. The company has also flagged that stricter U.S. export restrictions might pressure China-related tool orders. Reuters

The macro calendar is scrambled as well. MarketWatch noted the U.S. jobs report has been delayed to Feb. 11, with the CPI report now set for Feb. 13 due to the government shutdown. This postponement leaves investors uncertain about rate moves until mid-month. MarketWatch

Applied Materials is set to release its fiscal first-quarter results and host a conference call on Feb. 12 at 4:30 p.m. ET. Investors will be digging into guidance for 2026 spending and watching closely to see if the company’s recent customer orders are spreading out or remain focused. Nasdaq

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Johnson & Johnson stock price holds near $238 after-hours as Supreme Court talc case move hits
Previous Story

Johnson & Johnson stock price holds near $238 after-hours as Supreme Court talc case move hits

CrowdStrike stock sinks on insider sale plan as ‘software-mageddon’ rout bites CRWD
Next Story

CrowdStrike stock sinks on insider sale plan as ‘software-mageddon’ rout bites CRWD

Go toTop